16217-15-5

Usage

Uses

Used in Pharmaceutical Industry:
(S)-L-Benzyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxyl is used as a key intermediate for the preparation of dipeptidyl peptidase IV inhibitors. These inhibitors play a crucial role in managing type 2 diabetes by regulating blood glucose levels and are known for their potential in treating other related metabolic disorders.
Additionally, (S)-L-Benzyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxyl is used as a building block in the synthesis of (hydroxy)(carbamoyl)pyrimidinones. These compounds have demonstrated potent activity as HIV integrase inhibitors, which are vital in the development of antiretroviral drugs for the treatment of HIV/AIDS.

InChI:InChI=1/C14H15NO5/c1-19-13(17)12-7-11(16)8-15(12)14(18)20-9-10-5-3-2-4-6-10/h2-6,12H,7-9H2,1H3/t12-/m0/s1

Upstream product

• 132431-08-4 4-Oxo-pyrrolidine-2-carboxylic acid methyl ester 
• 501-53-1 benzyl chloroformate 
• 92246-88-3 N-carbobenzyloxy-trans-4-hydroxy-L-proline methyl ester 
• 79-37-8 oxalyl dichloride 
• 67-68-5 dimethyl sulfoxide 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 186581-53-3 diazomethane 
• 64187-47-9 1-benzyloxycarbonyl-4-keto-L-proline 
• 67-56-1 methanol 
• 64187-48-0 methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylate 
• 13504-85-3 (2S,4R)-1-(benzyloxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid 
• 57653-35-7 (2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-benzyl 2-methyl 
• 618-27-9 hydroxy L-proline 

Downstream Products

• 132431-08-4 4-Oxo-pyrrolidine-2-carboxylic acid methyl ester 
• 113490-83-8 2-<(phenylmethoxy)carbonyl>-6,10-dithia-2-azaspiro<4,5>-decane-3(S)-carboxylic acid methyl ester 
• 117653-35-7 2-methyl-1-(phenylmethyl) 4-<2-(1,1-dimethylethoxy)-2-oxoethylidene>-1,2-pyrrolidinedicarboxylate 
• 75776-76-0 7-<(phenylmethoxy)carbonyl>-1,4-dithia-7-azaspiro<4,4>-nonane-8(S)-carboxylic acid methyl ester 
• 113490-82-7 2-<(phenylmethoxy)carbonyl>-8,8-dimethyl-6,10-dioxa-2-azaspiro<4,5>-decane-3(S)-carboxylic acid methyl ester 
• 113490-84-9 N-<(phenylmethoxy)carbonyl>-4,4-bis(ethylthio)-(S)-proline methyl ester 
• 72180-26-8 4,4-difluoro-1-<(phenylmethoxy)carbonyl>-L-proline methyl ester 
• 934006-98-1 (2S,4R)-1-(tert-butoxycarbonyl)-4-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1,2-pyrrolidinecarboxylic acid 
• 147235-94-7 (2S,4R)-4-(carboxymethyl)pyrrolidine-2-carboxylic acid 
• 147235-94-7 (2S,4S)-4-(carboxymethyl)pyrrolidine-2-carboxylic acid 
• 168112-50-3 methyl (2S,4R)-4-<(menthyloxycarbonyl)methyl>pyrrolidine-2-carboxylate 
• 168034-52-4 methyl (2S,4S)-4-<(menthyloxycarbonyl)methyl>pyrrolidine-2-carboxylate 
• 168034-47-7 (2S,4R)-4-tert-Butoxycarbonylmethyl-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 
• 200184-60-7 (S)-N-benzyloxycarbonyl-4-methylenepyrrolidine-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Novel μ opioid antagonists derived from the μ opioid agonists endomorphin and [Dmt1]DALDA (H-Dmt-D-Arg-Phe-Lys-NH2)

Hybrid analogues of the μ opioid agonists endomorphin and [Dmt1]DALDA (H-Dmt-D-Arg-Phe-Lys-NH2, Dmt?=?2′,6′-dimethyltyrosine) containing cis-4-amino-Pro, trans-4-amino-Pro, cis-4-aminoethyl-Pro or cis-4-guanidinylethyl-Pro in the 2 p

BENZIMIDAZOLE-LINKED INDOLE COMPOUND ACTING AS NOVEL DIVALENT IAP ANTAGONIST

The present invention discloses a benzimidazole-linked indole compound acting as novel divalent IAP antagonist, specifically disclosing the compound shown in fomulas (I) or a pharmaceutically acceptable salt thereof.

Compound as apoptosis protein inhibitor, and application thereof

The present invention belongs to the field of medical chemistry, relates to a class of compounds of apoptosis protein inhibitors, and applications thereof, and particularly provides a compound represented by a formula I, or an isomer thereof, a pharmaceut

Oxyfunctionalization of the Remote C?H Bonds of Aliphatic Amines by Decatungstate Photocatalysis

Aliphatic amines, oxygenated at remote positions within the molecule, represent an important class of synthetic building blocks to which there are currently no direct means of access. Reported herein is an efficient and scalable solution that relies upon decatungstate photocatalysis under acidic conditions using either H2O2 or O2 as the terminal oxidant. By using these reaction conditions a series of simple and unbiased aliphatic amine starting materials can be oxidized to value-added ketone products. Lastly, NMR spectroscopy using in situ LED-irradiated samples was utilized to monitor the kinetics of the reaction, thus enabling direct translation of the reaction into flow.

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus

The design and synthesis of a series of tripeptide acylsulfonamides as potent inhibitors of the HCV NS3/4A serine protease is described. These analogues house a C4 aryl, C4 hydroxy-proline at the S2 position of the tripeptide scaffold. Information relatin

SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.

FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X', Y, Y', A, A',Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof, which can also be used for treating HCV infection or a HCV disorder.

Synthesis and biological evaluation of 4-hydroxy-4-(4-methoxyphenyl)- substituted proline and pyrrolidin-2-ylacetic acid derivatives as GABA uptake inhibitors

A series of enantiomerically pure 4-hydroxy-4-(4-methoxyphenyl)-substituted proline and pyrrolidin-2-ylacetic acid derivatives have been synthesized starting from the respective N-protected 4-hydroxy derivatives via oxidation to the corresponding 4-oxo co